CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC=Breast

The impact of erythropoiesis-stimulating agents administration

Alterations in immune cell phenotype and cytotoxic capacity in

Gemcitabine as adjuvant chemotherapy in patients with high-risk

Impact of HER2-low status for patients with early-stage breast

CONSORT 2010 explanation and elaboration: Updated guidelines for

Toxicity of external beam accelerated partial-breast irradiation

CONSORT 2010 explanation and elaboration: updated guidelines for

Safety, activity, and molecular heterogeneity following

PIK3CA alterations and benefit with neratinib: analysis from the

Clinico-pathologic features, treatment and outcomes of breast

CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC

The impact of erythropoiesis-stimulating agents administration

CONSORT diagram. aPatients who had surgery; bPatients with

National Surgical Adjuvant Breast and Bowel Project (NSABP)

The NSABP Experience